Cargando…
MIBG Therapy for Neuroblastoma: Precision Achieved With Dosimetry, and Concern for False Responders
Neuroblastoma causes 15% of cancer mortality in children. High risk neuroblastoma has poor prognosis, with high relapse rate and mortality despite multimodal treatment. 123-I-meta-iodo-benzyl-guanidine (mIBG) scintigraphy is one of the current standard diagnostic procedures in neuroblastoma. mIBG ca...
Autores principales: | Rubio, Pedro M., Galán, Victor, Rodado, Sonia, Plaza, Diego, Martínez, Leopoldo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270400/ https://www.ncbi.nlm.nih.gov/pubmed/32549040 http://dx.doi.org/10.3389/fmed.2020.00173 |
Ejemplares similares
-
The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro.
por: Armour, A., et al.
Publicado: (1997) -
EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours
por: Gear, Jonathan, et al.
Publicado: (2020) -
Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021) -
The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013) -
Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)